

<b>Form 1449 [SUPPLEMENTAL]</b>  <b>Information Disclosure Statement By Applicant</b>  (Use Several Sheets if Necessary)	<b>Atty Docket No.</b>	<b>UCSFP011X1</b>
	<b>Application No.:</b>	10/632,706
	<b>Applicant</b>	James D. Marks et al.
	<b>Filing Date</b>	August 1, 2003
	<b>Group</b>	1645
		Page 1 of 3

### U.S. Patent Documents

Examiner Initial	No.	Patent No.	Date	Patentee	Class	Sub-class	Filing Date
/NMM/	1.	60,648,256	01/27/05	Marks et al.			
	2.	2004/0265935	12/30/04	Atassi			
	3.	2004/0175385	09/09/04	Marks et al.			
	4.	USSN 11/342,271	01/26/06	Marks et al.			
	5.	5599539	02/04/97	Carroll, et al.			
	6.	5719267	02/17/98	Carroll, et al.			
	7.	5731161	03/24/98	Aoki, et al.			
	8.	5932449	08/03/99	Emanuel, et al.			
	9.	6461617	10/08/02	Shone, et al.			
	10.	6656468	12/02/03	Carroll, et al.			
	11.	6762280	07/13/04	Schmidt, et al.			
	12.	6794128	09/21/04	Marks, et al.			
	13.	7081529	07/25/06	Smith, et al.			
	14.	7157562	01/02/07	Olsen, II, et al.			
	15.	7192596	03/20/07	Shone, et al.			
	16.	7214787	05/08/07	Smith, et al.			
/NMM/	17.	7244826	07/17/07	Marks, et al.			

### Foreign Patent or Published Foreign Patent Application

Examiner Initial		Document No.	Publication Date	Country or Patent Office	Class	Sub-Class	Translation	
							Yes	No
/NMM/	18.	WO1996/025669	1996	PCT				
	19.	WO2004/106376	2004	PCT				
	20.	WO2005/084361	2005	PCT				
	21.	WO2005/016232	02/24/05	PCT				
	22.	WO2007/094754	01/26/06	PCT				
	23.	2006332045	01/26/06	AU				
/NMM/	24.	06849678.6	01/26/06	EP				

<b>Examiner</b> /N. M. Minnifield/ (06/22/2008)	<b>Date Considered</b>
--	------------------------

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>Form 1449 [SUPPLEMENTAL]</b>  <b>Information Disclosure Statement By Applicant</b>  (Use Several Sheets if Necessary)	<b>Atty Docket No.</b>	<b>UCSFP011X1</b>
	<b>Application No.:</b>	10/632,706
	<b>Applicant</b>	James D. Marks et al.
	<b>Filing Date</b>	August 1, 2003
	<b>Group</b>	1645
		Page 2 of 3

**Other Documents**

Examiner Initial	No.	Author, Title, Place (e.g. Journal) of Publication, Date
/NMM/	25.	PCT/US06/03070 International Search Report and Written Opinion dated 08/03/07 [Atty. Docket No. UCSFP008WO]
	26.	WO 2005/16232, International Search Report and Written Opinion dated 07/14/05 [Atty. Docket No. UCSFP011X1WO]
	27.	Amersdorfer and Marks (2000) <i>Meth. Mol Biol.</i> 145: 219-240.
	28.	Baldwin <i>et al.</i> (2005) <i>Infect. Immun.</i> , 73(10): 6998-7005.
	29.	Bartels <i>et al.</i> (1994) Specific antibodies against the Zn(2+)-binding domain of clostridial neurotoxins restore exocytosis in chromaffin cells treated with tetanus or botulinum A neurotoxin. <i>J Biol Chem.</i> 269(11): 8122-8127.
	30.	Bavari <i>et al.</i> Identifying the principal protective antigenic determinants of type A botulinum neurotoxin. <i>Vaccine.</i> 2002 vol 20, pp 1640-1648
	31.	Behzod <i>et al.</i> (2007) Immune recognition of botulinum neurotoxin B: Antibody-binding regions on the heavy chain of the toxin. <i>Mol Immunol.</i> [2007 Sep 24 Epub ahead of print]
	32.	Dixit <i>et al.</i> (2005) Characterization of Clostridium sp. RKD producing botulinum-like neurotoxin. <i>Systematic and Applied Microbiology</i> 28 405-414
	33.	Dixit <i>et al.</i> (2006) Development of an immunodetection test for a botulinum-like neurotoxin produced by Clostridium sp. <i>Indian J Med Res.</i> 124(3):355-362.
	34.	Doellgast <i>et al.</i> (1993) <i>J. Clin. Microbiol.</i> , 31(9): 2402-2409.
	35.	Doellgast <i>et al.</i> (1997) <i>J. Clin. Microbiol.</i> , 35(3): 578-583.
	36.	Garcia C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, Geren I, Stevens RC, and Marks JD. Molecular evolution of antibody specificity and cross reactivity for type A botulinum neurotoxins. <i>Nature Biotech.</i> 25:107-116, 2007.
	37.	Hall, Y.H.J., Novel Application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodies. <i>J. Immunological Methods</i> , 2004, Vol. 288, pp. 55-60
	38.	Levy R., Forsyth C.M., LaPorte S.L., Geren, I.N., Smith L.A., and Marks J.D. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. <i>J. Mol. Biol.</i> 365:196-210, 2007
/NMM/	39.	Lipps and Khan (2000) Antigenic cross reactivity among the venoms and toxins from unrelated diverse sources. <i>Toxicon.</i> 38(7): 973-980.

<b>Examiner</b> /N. M. Minnifield/ (06/22/2008)	<b>Date Considered</b>
--	------------------------

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>Form 1449 [SUPPLEMENTAL]</b>  <b>Information Disclosure Statement By Applicant</b>  (Use Several Sheets if Necessary)	<b>Atty Docket No.</b>	<b>UCSFP011X1</b>
	<b>Application No.:</b>	10/632,706
	<b>Applicant</b>	James D. Marks et al.
	<b>Filing Date</b>	August 1, 2003
	<b>Group</b>	1645
		Page 3 of 3

/NMM/	40.	Mah <i>et al.</i> (2003) Recombinant anti-botulinum neurotoxin A single-chain variable fragment antibody generated using a phage display system. <i>Hybrid Hybridomics</i> . 22(5): 277-283
	41.	O'Connell <i>et al.</i> (2007) Production of a recombinant antibody fragment in whole insect larvae. <i>Mol Biotechnol</i> . 36(1): 44-51
	42.	Oshima, et al., Immune recognition of botulinum neurotoxin type A: Regions recognized by T. cells and antibodies against the protective He fragment... 1997, <i>Molecular Imm.</i> 1997, Vol. 34, No. 14, pp. 1031-1040
	43.	Palys <i>et al.</i> (2006) Conversion of a mouse Fab into a whole humanized IgG antibody for detecting botulinum toxin. <i>Hum Antibodies</i> 15(4):125-132.
	44.	Park <i>et al.</i> (2003) Immunologic characterization of spasmodic dysphonia patients who develop resistance to botulinum toxin. <i>J Voice</i> . 17(2): 255-264.
	45.	Razai A, Garcia C, Lou J, Geren I, Forsyth C, Robles Y, Tsai R, Smith T, Smith LA, Siegel R, Feldhaus M, and Marks JD. Molecular evolution of antibody affinity for sensitive detection and neutralization of botulinum neurotoxin type A. <i>J. Mol. Biol.</i> 351:158-169, 2005.
	46.	Schmidt and Stafford (2005) Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity. <i>Biochemistry</i> 44(10): 4067-4073.
	47.	Sharma <i>et al.</i> (2006) <i>Appl Environ. Microbiol.</i> , 72(2): 1231-1238
	48.	Smith T, Lou J, Geren I, Forsyth C, Tsai R, Tepp WH, Bradshaw M, Johnson EA, Smith LA, and Marks JD. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. <i>Infect. Immun.</i> 73:5450-5457, 2005.
↓	49.	Tsuzuki <i>et al.</i> (1988) <i>Infect. Immun.</i> , 56(4): 898-902
/NMM/	50.	Wu <i>et al.</i> (2001) <i>Applied and Environmental Microbiology</i> 67(7): 3201-3207

<b>Examiner</b> /N. M. Minnifield/ (06/22/2008)	<b>Date Considered</b>
---	------------------------

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.